Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
September 2013 Volume 32 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
September 2013 Volume 32 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells

  • Authors:
    • Yusuke Tajitsu
    • Ryuji Ikeda
    • Yukihiko Nishizawa
    • Hirofumi Mataki
    • Xiao-Fang Che
    • Tomoyuki Sumizawa
    • Mina Nitta
    • Tatsuya Yamaguchi
    • Masatatsu Yamamoto
    • Sho Tabata
    • Shin-Ichi Akiyama
    • Katsushi Yamada
    • Tatsuhiko Furukawa
    • Yasuo Takeda
  • View Affiliations / Copyright

    Affiliations: Department of Clinical Pharmacy and Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan, Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan, Department of Domestic Science, Kagoshima Women's College, Kagoshima 890-8565, Japan, Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan, Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki 859-3298, Japan
  • Pages: 703-708
    |
    Published online on: July 2, 2013
       https://doi.org/10.3892/ijmm.2013.1428
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Major vault protein (MVP) is identical to lung resistance-related protein (LRP), which is the major component of vaults. Vaults are considered to play a protective role against xenobiotics and other types of stress. In a previous study, we reported that the expression levels of MVP in SW620 human colon cancer cells were increased in hypertonic culture medium with sucrose. However, the molecular mechanism behind the induction of MVP expression by osmotic stress has not yet been elucidated. Therefore, in the present study, we investigated the mechanism behind the induction of MVP expression by osmotic stress. Under hyperosmotic stress conditions, the ubiquitination of specificity protein 1 (Sp1) decreased, Sp1 protein levels increased, its binding to the MVP promoter was enhanced, and small interfering RNA (siRNA) for Sp1 suppressed the induction of MVP expression. The inhibition of c-jun N-terminal kinase (JNK) by SP600125, a specific JNK inhibitor, decreased the expression of MVP and Sp1 under hyperosmotic conditions. Our data indicate that the stabilization and upregulation of Sp1 protein expression by JNK participate in the inhibition of the ubiquitination and degradation of Sp1, and thus in the induction of MVP expression under hyperosmotic conditions.

Introduction

Vaults are predominantly cytoplasmic ribonucleoprotein particles identified in preparations of coated vesicles (1). The vault complex has a barrel-like structure with an invaginated waist and two protruding caps. Mammalian vaults are composed of major vault protein (MVP) and two minor vault proteins [vault poly(ADP-ribose)polymerase (VPARP) and telomerase-associated protein 1 (TEP1)] as well as small untranslated RNAs (2). Vault particles have been highly conserved throughout evolution and are found in numerous eukaryotic species (3). These data suggest that vaults have an important cellular function. However, the precise function of vault particles has not yet been completely elucidated.

MVP is the main component of vault particles and covers over 70% of the particle mass. Since MVP is identical to lung resistance-related protein (LRP), which was first identified in a non-P-gp multidrug-resistant cancer cell line and has been shown to be overexpressed in several multidrug resistant cell lines (4,5), it has been suggested that MVP is involved in multidrug resistance.

On the other hand, a number of previous studies have reported that MVP expression is induced by a variety of cellular stresses such as DNA damaging agents, UV irradiation, hypoxia and hyperthermia (6–8). Kowalski et al (9) reported that MVP is involved in host resistance to infection with Pseudomonas aeruginosa. Ryu et al (10) demonstrated that MVP enhanced the resistance of cells to apoptosis induced by H2O2 in senescent human diploid fibroblasts (HDFs). These findings suggest that MVP plays an important role in cellular responses to stress.

It has previously been reported that the human MVP promoter lacks a TATA-box, as well as other core promoter elements, but harbors putative transcriptional factor binding sites for p53, STAT1, MyoD, specificity protein 1 (Sp1), GATA and YB-1 (11). Transcription factors are involved in the regulation of MVP in different cell types (6–9,12,13). We previously reported that hyperosmotic stress upregulated the expression of MVP (14). However, it is unclear which transcription factor affects MVP expression under hyperosmotic stress conditions and the underlying mechanism has not yet been elucidated. Therefore, the aim of this study was to investigate the mechanism behind the induction of MVP expression under hyperosmotic stress conditions.

Materials and methods

Cell line, antibodies and chemicals

The SW620 human colon carcinoma cell line was provided by Dr A.T. Fojo (National Cancer Institute, Bethesda, MD, USA). HA-tagged ubiquitin for constructing the plasmid was provided by Dr Dirk Bohmann (European Molecular Biology Laboratory, Heidelberg, Germany). RPMI-1640 medium was purchased from Nissui Seiyaku Co. (Tokyo, Japan). Fetal calf serum (FCS) was obtained from JRH Biosciences (Lenexa, KS, USA). Sucrose was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). A rabbit anti-ERK polyclonal antibody (C-16), mouse anti-Sp1 monoclonal antibody (E-3), rabbit anti-Sp1 polyclonal antibody (PEP2), rabbit anti-HA polyclonal antibody (Y-11) and mouse phosphothreonin monoclonal antibody (H-2) were obtained from Santa Cruz Biotechnology, Inc. A mouse anti-STAT1 monoclonal antibody (610185) was obtained from BD Biosciences. A rabbit anti-MVP polyclonal antibody was prepared using a glutathione S-transferase (GST)-MVP (aa 694–794) fusion protein as an antigen (5).

Immunoblot analysis

Immunoblot analysis was carried out as described previously (5,17).

Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA from cultured cells was isolated using TRIzol reagent (Invitrogen). RT-PCR was performed with the SuperScript One-Step RT-PCR system and gene-specific primers according to the manufacturer’s instructions (Invitrogen). Reaction mixtures contained total RNA (500 ng of each), 0.2 mM dNTPs, 0.2 μM of Sp1 primer (sense, 5′-TGGAAGCAGCTGAGGCAATGG-3′ and antisense, 5′-ATCCAGCCTCAGCTAGTTCAA-3′) and GAPDH primer (sense, 5′-AGAACATCATCCCTGCCTCTA CTGG-3′ and antisense, 5′-AAAGGTGGAGGAGTGGGTGT CGCTG-3′), enzyme mixture containing SuperScript II RT, Platinum TaqDNA polymerase, and 1X buffer with 1.2 mM MgSO4. The reaction was performed at 50ºC for 20 min, 94ºC for 2 min, followed by 28 cycles of 94ºC for 15 sec, 55ºC for 30 sec and 70ºC for 30 sec.

Dual-luciferase reporter assay

The generation of the MVP promoter-luciferase construct (pMVP78) has been described in a previous study of ours (6). The luciferase assay was performed using the Dual-Luciferase Reporter Assay System according to the manufacturer’s instructions (Promega). In order to perform the luciferase assay, transfected SW620 cells were cultured in the presence of sucrose. Cells were washed with PBS and lysed using 100 μl of passive lysis buffer per well. Luminescence assays were performed using a luminometer (TD-20/20 Luminometer; Turner Designs, Sunnyvale, CA, USA). All experiments were performed in triplicate and the results were normalized to pRL-TK activity.

RNA interference

STAT1 siRNA was obtained from Cell Signaling Technology (no. 6544). siRNA duplexes were synthesized using the Silencer™ siRNA construction kit (Ambion Inc., Austin, TX, USA). The siRNA used in this study consisted of a 21-nucleotide sense strand and a 21-nucleotide antisense strand with a two-nucleotide overhang at the 3′-end. Sequences were as follows: GFP-siRNA target sequence, 5′-AAGCGTTCAACTA GCAGACCA-3′; Sp1-siRNA target sequence, 5′-AAGGAA CAGAGTGGCAGCAGT-3′. siRNA (100 nM) was introduced into the SW620 cells using Lipofectamine™ 2000 according to the manufacturer’s instructions (Invitrogen).

In vitro ubiquitination assays

COS-7 cells were transfected with expression vectors encoding HA-tagged ubiquitin for 24 h after transfection, and were exposed for 12 h to normal osmotic or hyperosmotic conditions in the presence of the proteasome inhibitor, MG132 (5 μM). The cells were then lysed in RIPA buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40 (NP-40), 0.1% SDS, 0.5% sodium deoxycholate, 1 mM p-amidinophenyl methanesulfonyl fluoride hydrochloride (APMSF) and 1 mg/ml aprotinin] and lysates (500 μg protein) were immunoprecipitated with anti-Sp1 antibody followed by immunoblotting with anti-HA antibody.

Immunoprecipitation

Cells were lysed with RIPA buffer and centrifuged at 7,500 rpm for 10 min at 4ºC. Subsequent to protein extraction, 500 μg of total cell lysates were incubated with anti-Sp1 monoclonal antibody at 4ºC for 1 h. A total of 30 μl of a 50% slurry of protein G-Sepharose 4B in RIPA buffer was then added to the reaction mixtures and incubated for 12 h at 4ºC with rotation. Following rapid centrifugation, the resulting pellets were washed three times with RIPA buffer, and the immunoprecipitated proteins were analyzed by immunoblotting using anti-phosphothreonin antibody or anti-Sp1 polyclonal antibody.

Chromatin immunoprecipitation (ChIP) assay

Cells were fixed with 1% formaldehyde for 10 min at 37ºC to cross-link protein to DNA. A chromatin immunoprecipitation (ChIP) assay was carried out using a ChIP assay kit (Upstate Biotechnology), according to the manufacturer’s instructions. The soluble DNA fraction was mixed with an anti-Sp1 polyclonal antibody or non-immunized rabbit IgG (Santa Cruz Biotechnology), and the precipitated DNA was amplified with primers for the MVP promoter [5′-GCCAGCTGGCTCCAAGGTAG-3′ (sense) and 5′-ATCACTTCCCGGCAGGGCAA-3′ (antisense)].

Results

Sp1 directly regulates the transcription of the MVP gene under hyperosmotic stress conditions

We previously reported that hyperosmotic stress upregulates MVP promoter activity. To identify important MVP promoter elements that are involved in the induction of MVP expression by hyperosmotic stress, we generated luciferase reporter constructs containing various promoter elements. The pMVP78 construct contained three elements, Sp1, p53 and STAT, which were reported as transcription factors involved in MVP promoter activity (Fig. 1A). Following the transfection of the plasmids into the SW620 cells, cells were subjected to hyperosmotic stress and MVP promoter activity was monitored by luciferase assay. Compared to basal luciferase activity, luciferase activity was approximately 2-fold higher in the pMVP78-transfected cells treated with sucrose (Fig. 1B). These results suggest that Sp1, p53, or STAT contribute to the enhancement of MVP promoter activity by hyperosmotic stress.

Figure 1

(A) Outline of the MVP-promoter constructs used. The top line indicates the promoter region (−407) upstream of the MVP transcription start site (+1). The pMVP78 construct harbors the Sp1, p53 and STAT binding sites. This construct was linked to a luciferase reporter gene (luc). (B) SW620 cells were transiently transfected with pMVP78 (800 ng) and pRL-TK (200 ng) reporter gene constructs using Lipofectamine 2000 reagent. After transfection, the cells were incubated in the presence (+) or absence (-) of 100 mM sucrose for 48 h and then assayed for luciferase activity. Experiments were performed in triplicate and the results were normalized to pRL-TK activity. Bars indicated the means ± SD. *P<0.05. (C) SW620 cells were transfected with siRNA targeting Sp1, STAT1, or GFP and cultured in 100 mM sucrose for 48 h, and cell lysates were tehn prepared from these cells. The expression of Sp1, STAT1, MVP and ERK-1 was detected by immunoblot analsyis using anti-Sp1, anti-STAT1, anti-MVP and anti-ERK-1 antibodies, respectively. (D) The SW620 cells were treated with 100 mM sucrose for 72 h. Cells were fixed with formaldehyde to form a DNA-protein complex and were subjected to ChIP assay, as described in Materials and methods. A PCR primer for the MVP promoter was used to detect the promoter fragments in the immunoprecipitates. The input lane represents 20% of the total chromatin used in the ChIP assay.

SW620 cells have a mutation in the p53 gene (codon 273, Arg→His). This suggests that Sp1 or STAT1 is involved in the induction of MVP expression by hyperosmotic stress. To determine whether Sp1 or STAT1 are involved in the induction of MVP by hyperosmotic stress, SW620 cells were transfected with siRNA targeting Sp1 or STAT1. Sp1 knockdown inhibited the induction of MVP expression by hyperosmotic stress in the SW620 cells (Fig. 1C). However, STAT1 knockdown did not affect the induction of MVP expression. These results suggest that Sp1 is involved in the induction of MVP expression by hyperosmotic stress in SW620 cells.

To determine whether Sp1 can bind to the promoter region of the MVP gene in SW620 cells under hyperosmotic stress conditions, we performed a chromatin immunoprecipitation (ChIP) assay using anti-Sp1 antibody. The presence of the MVP promoter in chromatin immunoprecipitates was assessed by PCR using a specific pair of primers spanning the Sp1-bind site in the MVP gene promoter. Sp1 recruitment to the MVP promoter was enhanced by hyperosmotic stress in SW620 cells (Fig. 1D). These results indicate that Sp1 directly regulates the transcription of the MVP gene under hyperosmotic stress conditions.

Hyperosmotic stress upregulates Sp1 protein levels

To determine whether hyperosmotic stress affects the expression of Sp1, we performed immunoblot analysis using anti-Sp1 antibody. Fig. 2A shows that the expression of Sp1 increased with increasing concentrations of sucrose from 50 to 200 mM. Sp1 protein levels increased in a time-dependent manner during treatment with sucrose at 100 mM, and achieved a peak at 12 h (Fig. 2B).

Figure 2

Effect of osmotic stress on Sp1 expression levels in SW620 cells. (A and B) SW620 cells were incubated in (A) 0–200 mM sucrose for 8 h, or (B) 100 mM sucrose for 24 h. After incubation, cell lysates were prepared and analyzed for Sp1 and ERK-1 protein expression by immunoblot analysis using anti-Sp1 or anti-ERK-1 antibodies. (C and D) SW620 cells were incubated in (C) 0–200 mM sucrose for 8 h, or (D) 100 mM sucrose for 8 h. After incubation, cell lysates were prepared and analyzed for Sp1 mRNA by RT-PCR. The expression of GAPDH was used as the loading control.

We then examined the effect of hyperosmotic stress on the expression levels of Sp1 mRNA in SW620 cells. Hyperosmotic stress did not affect Sp1 mRNA levels (Fig. 2C and D). These results suggest that hyperosmotic stress upregulates Sp1 protein levels by reducing the turnover rate.

Hyperosmotic stress suppresses proteasome-dependent Sp1 degradation by inhibiting ubiquitination

To examine the possibility that the accumulation of Sp1 protein reflects a reduction in its degradation rate, we investigated whether the induction of Sp1 expression by hyperosmotic stress occurs in SW620 cells exposed to cycloheximide.

As shown in Fig. 3A, cycloheximide did not inhibit the induction of Sp1 expression under hyperosmotic conditions. This result suggests that the degradation of Sp1 may be suppressed under hyperosmotic conditions. We therefore investigated the effect of MG132, a proteasome inhibitor, on Sp1 protein levels. Proteasome inhibition in the SW620 cells by MG132 increased Sp1 protein levels (Fig. 3B). To determine whether hyperosmotic stress affects the ubiquitination of Sp1, COS-7 cells were transfected with HA-tagged ubiquitin. The transfected cells were then incubated for 12 h under hyperosmotic conditions in the presence or absence of MG132. Ubiquitinated Sp1 was detected by immunoblot analsyis using anti-HA antibody following immunoprecipitation with anti-Sp1 antibody. Furthermore, as shown in Fig. 3C, hyperosmotic stress suppressed the ubiquitination of Sp1. These results suggest that hyperosmotic stress induces the accumulation of Sp1 by suppressing its ubiquitination.

Figure 3

(A) SW620 cells were treated with sucrose in the presence or absence of cyclohexymide. Cell lysates were prepared from these cells. The expression of Sp1 and ERK-1 was detected by immunoblot analysis using antibodies against Sp1 or ERK-1. (B) Effect of the proteasome inhibitor, MG132, on the expression of Sp1 in SW620 cells. SW620 cells were incubated in 0–10 μM MG132. Cell lysates were prepared from these cells. The expression of Sp1 and ERK-1 was detected by immunoblot analysis using antibodies against Sp1 or ERK-1. (C) COS-7 cells were transfected with a vector encoding HA-tagged ubiquitin. Transfected cells were treated with sucrose for 12 h in the presence or absence of MG132 (5 μM). Ubiquitinated proteins were immunoprecipitated with anti-Sp1 antibody, and ubiquitinated Sp1 was detected by immunoblot analysis using anti-HA antibody.

Induction of Sp1 is mediated by the activation of c-Jun N-terminal kinase (JNK) activation under hyperosmotic stress conditions

Hyperosmotic stress activates JNK, which plays an important role in cellular stress responses. A recent study showed that threonine phosphorylation by JNK-1 regulates the stability of Sp1 (15). In order to investigate whether JNK is activated in SW620 cells under hyperosmotic stress conditions, we analyzed the phosphorylation of JNK in SW620 cells under hyperosmotic stress conditions. The phosphorylation of JNK increased in a manner dependent on the sucrose concentration, which was increased from 50 to 200 mM (Fig. 4A). These data suggest that hyperosmotic stress activates JNK in SW620 cells.

Figure 4

(A) SW620 cells were incubated in 0–200 mM sucrose for 1 h, lysed, and analyzed for phosphorylated JNK and JNK by immunoblot analysis using anti-phosphorylated JNK or anti-JNK antibodies. (B) SW620 cells were incubated in 100 mM sucrose for 12 h. Phosphorylated proteins were immunoprecipitated with anti-Sp1 antibody, and phospho-threonine levels of Sp1 were detected by immunoblot analysis with anti-phospho-threonine antibody. (C) SW620 cells were treated with 100 mM sucrose in the presence or absence of SP600125. After incubation, phosphorylated proteins were immunoprecipitated with anti-Sp1 antibody, and phospho-threonine levels of Sp1 were detected by immunoblot analysis with anti-phospho-threonine antibody. (D and E) SW620 cells were treated with 100 mM sucrose in the presence or absence of SP600125. After incubation, cell lysates were prepared and analyzed for (D) Sp1 and (E) MVP by immunoblot analysis. Blotting of ERK-1 was used as the loading control.

Therefore, we investigated the threonine phosphorylation of Sp1 under hyperosmotic stress conditions to confirm that hyperosmotic stress affects the threonine phosphorylation of Sp1 in SW620 cells. Hyperosmotic stress increased the threonine phosphorylation of Sp1 (Fig. 4B). Moreover, as shown in Fig. 4C, SP600125, a specific JNK inhibitor, inhibited the phosphorylation of Sp1 under hyperosmotic conditions.

To investigate whether JNK regulates the induction of Sp1 and MVP by hyperosmotic stress, SW620 cells were treated with SP600125 in the presence or absence of hyperosmotic stress. SP600125 inhibited the induction of Sp1 expression and consequently that of MVP under hyperosmotic stress conditions (Fig. 4D and E). These data suggest that JNK upregulates MVP expression by inhibiting Sp1 degradation under hyperosmotic stress conditions. Therefore, the stability of Sp1 may be mediated by the enhancement of Sp1 phosphorylation by JNK under hyperosmotic stress conditions.

Discussion

One of the cellular stresses to which cells are exposed to in vivo is hyperosmotic stress. It has previously been reported that hyperosmotic stress induces apoptosis of cells (16). We previously reported that hyperosmotic stress modulates the PI3K/Akt pathway and induces MVP, which exerts a cytoprotective effect against apoptosis, thereby preventing cells from undergoing apoptosis by the activation of Akt in SW620 colon cancer cells (14). However, the molecular basis for the expression of MVP induced by hyperosmotic stress is unclear. Therefore, in the current study, we elucidated that Sp1 and JNK regulate the expression of MVP under hyperosmotic conditions.

Our results showed that hyperosmotic stress enhanced the binding of Sp1 to the MVP promoter and upregulated the transcription of the MVP gene. Sp1 is ubiquitous in mammalian cells and is known as a housekeeping gene and a transcription factor with a C2H2 zinc finger DNA binding domain, and also modulates transcription of numerous genes (17). It has been reported that Sp1 is activated by osmotic changes and regulates the transcription of a number of genes (18,19). Our data are consistent with these data from previous reports. Moreover, it has also been reported that the knockdown of Sp1 enhances the H2O2-induced apoptosis of U2OS osteosarcoma cells (20). We previously reported that MVP prevents cells from undergoing apoptosis (14). Our findings, as well as those from previous reports suggest that Sp1 augments the expression of MVP and consequently protects cells from apoptosis under hyperosmotic conditions.

JNK belongs to the family of mitogen-activated protein kinases (MAPKs) and is activated by several types of cellular stress, such as hypoxia and osmotic stress (21,22). This study demonstrates that the inhibition of the ubiquitination and degradation of Sp1 by JNK causes the stabilization and upregulation of Sp1 protein, which participates in the induction of MVP expression under hyperosmotic stress conditions. Chuang et al (15) reported that the phosphorylation by JNK-1 regulates the stability of transcription factor Sp1 during mitosis. We previously reported that the expression levels of MVP in S1 small cell lung cancer cells increased in hypertonic culture medium with sucrose (14). As Sp1 protein levels also increased in S1 cells (data not shown), JNK may regulate the expression of MVP under hyperosmotic stress conditions in other cell lines. Recent studies have shown that JNK suppresses the interaction between Sp1 and ring finger protein 4 (RNF4), which is an E3 ubiquitin ligase of Sp1 (15,23). These data suggest that JNK is activated by hyperosmotic stress and may suppress the interaction between Sp1 and RNF4 by phosphorylating the threonine residue of Sp1. Consistent with these data, the results from our study showed that hyperosmotic stress enhanced the threonine phosphorylation of Sp1 and decreased the ubiquitination of Sp1 (Figs. 3C and 4B).

We previously reported that p38 MAPK, which belongs to the family of MAPKs and is activated by cellular stress, is partly involved in the expression of MVP induced by hyperosmolytes. However, SB203580, a p38 MAPK-specific inhibitor, did not affect the induction of Sp1 by hyperosmotic stress (data not shown). These data suggest that p38 MAPK activates Sp1 without affecting the expression of Sp1 under hyperosmotic conditions. In fact, certain studies have shown that p38 MAPK activates Sp1 (24,25). Further studies are required to define the role of p38 MAPK under hyperosmotic conditions.

In conclusion, the expression of MVP is upregulated by several types of cellular stress. The data from our study indicate that hyperosmotic stress upregulates Sp1 expression levels by inhibiting ubiquitination through the activation of JNK, and the induction of Sp1 expression directly enhances MVP transcription.

Acknowledgements

We thank Dr Dirk Bohmann (European Molecular Biology Laboratory, Heidelberg, Germany) for providing the HA-tagged ubiquitin plasmid.

References

1 

Kedersha NL and Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol. 103:699–709. 1986. View Article : Google Scholar : PubMed/NCBI

2 

Kickhoefer VA, Vasu SK and Rome LH: Vaults are the answer, what is the question? Trends Cell Biol. 6:174–178. 1996. View Article : Google Scholar : PubMed/NCBI

3 

Kedersha NL, Miquel MC, Bittner D and Rome LH: Vaults. II Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol. 110:895–901. 1990. View Article : Google Scholar : PubMed/NCBI

4 

Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med. 1:578–782. 1995. View Article : Google Scholar : PubMed/NCBI

5 

Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and Akiyama S: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst. 91:1647–1653. 1999. View Article : Google Scholar : PubMed/NCBI

6 

Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, Sakata R and Akiyama S: Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep. 15:645–652. 2006.PubMed/NCBI

7 

Stein U, Jürchott K, Schläfke M and Hohenberger P: Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol. 20:3282–3292. 2002. View Article : Google Scholar

8 

Iwashita K, Ikeda R, Takeda Y, Sumizawa T, Furukawa T, Yamaguchi T, Akiyama S and Yamada K: Major vault protein forms complexes with hypoxia-inducible factor (HIF)-1alpha and reduces HIF-1alpha level in ACHN human renal adenocarcinoma cells. Cancer Sci. 101:920–926. 2010. View Article : Google Scholar

9 

Kowalski MP, Dubouix-Bourandy A, Bajmoczi M, Golan DE, Zaidi T, Coutinho-Sledge YS, Gygi MP, Gygi SP, Wiemer EA and Pier GB: Host resistance to lung infection mediated by major vault protein in epithelial cells. Science. 317:130–132. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Ryu SJ, An HJ, Oh YS, Choi HR, Ha MK and Park SC: On the role of major vault protein in the resistance of senescent human diploid fibroblasts to apoptosis. Cell Death Differ. 15:1673–1680. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Lange C, Walther W, Schwabe H and Stein U: Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene promoter. Biochem Biophys Res Commun. 278:125–133. 2000. View Article : Google Scholar : PubMed/NCBI

12 

Stein U, Bergmann S, Scheffer GL, Scheper RJ, Royer HD, Schlag PM and Walther W: YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene. 24:3606–3618. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M and Berger W: SP-transcription factors are involved in basal MVP promoter activity and its stimulation by HDAC inhibitors. Biochem Biophys Res Commun. 317:235–243. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Ikeda R, Iwashita K, Sumizawa T, Beppu S, Tabata S, Tajitsu Y, Shimamoto Y, Yoshida K, Furukawa T, Che XF, Yamaguchi T, Ushiyama M, Miyawaki A, Takeda Y, Yamamoto M, Zhao HY, Shibayama Y, Yamada K and Akiyama S: Hyperosmotic stress up-regulates the expression of major vault protein in SW620 human colon cancer cells. Exp Cell Res. 314:3017–3026. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Chuang JY, Wang YT, Yeh SH, Liu YW, Chang WC and Hung JJ: Phosphorylation by c-Jun NH2-terminal kinase 1 regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell. 19:1139–1151. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Mak SK and Kültz D: Gadd45 proteins induce G2/M arrest and modulate apoptosis in kidney cells exposed to hyperosmotic stress. J Biol Chem. 279:39075–39084. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Kadonaga JT, Carner KR, Masiarz FR and Tjian R: Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 51:1079–1090. 1987. View Article : Google Scholar : PubMed/NCBI

18 

Ramos A, Ho WC, Forte S, Dickson K, Boutilier J, Favell K and Barker PA: Hypo-osmolar stress induces p75NTR expression by activating Sp1-dependent transcription. J Neurosci. 27:1498–1506. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Bell LM, Leong ML, Kim B, Wang E, Park J, Hemmings BA and Firestone GL: Hyperosmotic stress stimulates promoter activity and regulates cellular utilization of the serum- and glucocorticoid-inducible protein kinase (Sgk) by a p38 MAPK-dependent pathway. J Biol Chem. 275:25262–25272. 2000. View Article : Google Scholar

20 

Olofsson BA, Kelly CM, Kim J, Hornsby SM and Azizkhan-Clifford J: Phosphorylation of Sp1 in response to DNA damage by ataxia telangiectasia-mutated kinase. Mol Cancer Res. 5:1319–1330. 2007. View Article : Google Scholar : PubMed/NCBI

21 

Huangfu WC, Omori E, Akira S, Matsumoto K and Ninomiya-Tsuji J: Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-kappaB activation TAO2 regulates TAK1 pathways. J Biol Chem. 281:28802–28810. 2006. View Article : Google Scholar : PubMed/NCBI

22 

Ho CY and Li HY: DNA damage during mitosis invokes a JNK-mediated stress response that leads to cell death. J Cell Biochem. 110:725–731. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Wang YT, Yang WB, Chang WC and Hung JJ: Interplay of posttranslational modifications in Sp1 mediates Sp1 stability during cell cycle progression. J Mol Biol. 414:1–14. 2011. View Article : Google Scholar : PubMed/NCBI

24 

D’Addario M, Arora PD, Ellen RP and McCulloch CA: Interaction of p38 and Sp1 in a mechanical force-induced, beta 1 integrin-mediated transcriptional circuit that regulates the actin-binding protein filamin-A. J Biol Chem. 277:47541–47550. 2002.

25 

Lin HH, Lai SC and Chau LY: Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. J Biol Chem. 286:3829–3838. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Tajitsu Y, Ikeda R, Nishizawa Y, Mataki H, Che X, Sumizawa T, Nitta M, Yamaguchi T, Yamamoto M, Tabata S, Tabata S, et al: Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells. Int J Mol Med 32: 703-708, 2013.
APA
Tajitsu, Y., Ikeda, R., Nishizawa, Y., Mataki, H., Che, X., Sumizawa, T. ... Takeda, Y. (2013). Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells. International Journal of Molecular Medicine, 32, 703-708. https://doi.org/10.3892/ijmm.2013.1428
MLA
Tajitsu, Y., Ikeda, R., Nishizawa, Y., Mataki, H., Che, X., Sumizawa, T., Nitta, M., Yamaguchi, T., Yamamoto, M., Tabata, S., Akiyama, S., Yamada, K., Furukawa, T., Takeda, Y."Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells". International Journal of Molecular Medicine 32.3 (2013): 703-708.
Chicago
Tajitsu, Y., Ikeda, R., Nishizawa, Y., Mataki, H., Che, X., Sumizawa, T., Nitta, M., Yamaguchi, T., Yamamoto, M., Tabata, S., Akiyama, S., Yamada, K., Furukawa, T., Takeda, Y."Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells". International Journal of Molecular Medicine 32, no. 3 (2013): 703-708. https://doi.org/10.3892/ijmm.2013.1428
Copy and paste a formatted citation
x
Spandidos Publications style
Tajitsu Y, Ikeda R, Nishizawa Y, Mataki H, Che X, Sumizawa T, Nitta M, Yamaguchi T, Yamamoto M, Tabata S, Tabata S, et al: Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells. Int J Mol Med 32: 703-708, 2013.
APA
Tajitsu, Y., Ikeda, R., Nishizawa, Y., Mataki, H., Che, X., Sumizawa, T. ... Takeda, Y. (2013). Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells. International Journal of Molecular Medicine, 32, 703-708. https://doi.org/10.3892/ijmm.2013.1428
MLA
Tajitsu, Y., Ikeda, R., Nishizawa, Y., Mataki, H., Che, X., Sumizawa, T., Nitta, M., Yamaguchi, T., Yamamoto, M., Tabata, S., Akiyama, S., Yamada, K., Furukawa, T., Takeda, Y."Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells". International Journal of Molecular Medicine 32.3 (2013): 703-708.
Chicago
Tajitsu, Y., Ikeda, R., Nishizawa, Y., Mataki, H., Che, X., Sumizawa, T., Nitta, M., Yamaguchi, T., Yamamoto, M., Tabata, S., Akiyama, S., Yamada, K., Furukawa, T., Takeda, Y."Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells". International Journal of Molecular Medicine 32, no. 3 (2013): 703-708. https://doi.org/10.3892/ijmm.2013.1428
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team